Cite
Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency.
MLA
Hermans, Cedric, et al. “Dabigatran Etexilate (Pradaxa®) for Preventing Warfarin-Induced Skin Necrosis in a Patient with Severe Protein C Deficiency.” Thrombosis and Haemostasis, vol. 107, no. 6, June 2012, pp. 1189–91. EBSCOhost, https://doi.org/10.1160/TH11-11-0788.
APA
Hermans, C., Eeckhoudt, S., & Lambert, C. (2012). Dabigatran etexilate (Pradaxa®) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thrombosis and Haemostasis, 107(6), 1189–1191. https://doi.org/10.1160/TH11-11-0788
Chicago
Hermans, Cedric, Stéphane Eeckhoudt, and Catherine Lambert. 2012. “Dabigatran Etexilate (Pradaxa®) for Preventing Warfarin-Induced Skin Necrosis in a Patient with Severe Protein C Deficiency.” Thrombosis and Haemostasis 107 (6): 1189–91. doi:10.1160/TH11-11-0788.